Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00451880 · ClinicalTrials.gov registry record · Phase 1
Study of XL281 in Adults With Solid Tumors
A Phase 1 study, sponsored by Exelixis.
- Completed
- Registry status
- Phase 1
- Development phase
- 180
- Enrollment target
NCT00451880 is a Phase 1 study that has completed, run by Exelixis. The registered enrollment target is 180 participants.
The verdict
NCT00451880, a Phase 1 study, has completed, sponsored by Exelixis.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 180 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL281 when it is taken with and without food, and with and without Pepcid (famotidine), a drug that inhibits stomach acid production.
Interventions
- DRUG famotidine
- DRUG XL281
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2007-02 |
| Est. Completion | 2011-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00451880
The ClinicalTrials.gov registry entry for NCT00451880 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 180 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which famotidine is the first listed.
NCT00451880 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00451880 about?
NCT00451880 is a clinical study titled "Study of XL281 in Adults With Solid Tumors". The purpose of this study is to determine the safest dose of the multiple Raf kinase inhibitor (including c-Raf, B-Raf, and the activated mutant B-RafV600E) XL281, how often it should be taken, and how well subjects with cancer tolerate XL281. This study will also determine how the body reacts to XL...
What is the current status of trial NCT00451880?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 180 participants. The study started on 2007-02. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00451880?
The interventions under investigation include: famotidine (DRUG), XL281 (DRUG).
Who is sponsoring clinical trial NCT00451880?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.